Solid Biosciences Inc. (SLDB) Forward P/S Multiple

solidbio.com (SLDB) - corporate logo

The success of SGT-003 trials and the patent protection of Solid Biosciences Inc. (SLDB) make the company an attractive acquisition target, while the absence of pricing disputes shifts the focus toward therapy safety. This chart of the company's expected P/S ratio demonstrates the impact of costs on revenue forecasts, where the current figure stands at 11.90. Business stability is underpinned by the development of treatments for rare genetic pathologies within US centers.

solidbio.com - SLDB Market Cap to Expected Sales Ratio (period 07/04/2022 - 08/19/2023)

Solid Corp - analytical breakdowns and key metrics (SLDB)

- market price and analyst price targets:
Price Chart Solid Biosciences|SLDB - Analyst Median Target
- market capitalization details:
Market Capitalization Solid Corp|SLDB - Real Price to Acquire Entire Company
- issuer book value statistics:
Book Value per Share Solid Biosciences|SLDB - Book Valuation of Business|Market Capitalization to Book Value Ratio solidbio.com|SLDB - Company Assets
- debt level and financial liquidity data:
Debt to Equity Solid Biosciences Inc.|SLDB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Solid Biosciences Inc.|SLDB - Company Total Debt|Debts to Book Capitalization Solid Corp|SLDB - Long-Term Debt|Company Short-Term Debt Solid Biosciences|Quick Liquidity Indicator solidbio.com
- financial results and valuation multiples details:
SLDB - Final Profit|Projected Future Earnings Solid Biosciences Inc.|SLDB - Business Payback Period|Future Price to Earnings Solid Bio|SLDB - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Solid Corp|SLDB - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Solid Biosciences|SLDB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months solidbio.com|SLDB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Solid Biosciences Inc.
- sales volume and revenue indicators:
SLDB - Company Revenue|Projected Sales Volume Solid Biosciences|SLDB - Market Cap to Revenue Ratio|Forward P/S Multiple Solid Corp
Analysis of all company metrics:Solid Biosciences SLDB
Original product of Solid Corp

Forward P/S determines the market value of one dollar of expected sales, allowing an investor to promptly assess asset overvaluation without the delays of quarterly reporting. By analyzing the forward P/S trend, one can confirm the justification for high multiples through the exclusivity of Solid Biosciences Inc. (SLDB) gene therapy, where patent protection and the lack of alternative treatments create a foundation for ultra-high-margin revenues and a long-term market monopoly.

Competitor analysis

Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|Market Cap to Expected Sales Ratio Qiagen NV (QGEN)|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA: Forward P/S Multiple|CRSP - Market Cap to Expected Sales Ratio|WGS (GeneDx) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Ultragenyx Pharmaceutical Inc. RARE|Price-to-Projected Revenue Ratio Beam Therapeutics Corp (BEAM)|Sarepta Corp - Market Cap to Projected Revenue|Forward P/S Multiple TWST (Twist Bioscience)|TXG - Forward Price-to-Revenue Multiple|Intellia Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stoke Therapeutics Inc|BioLife Corp (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|SION: Forward Price to Sales|Forward P/S Multiple PRME|Market Cap to Expected Sales Ratio Taysha Gene Therapies Inc|Price-to-Projected Revenue Ratio uniQure Corp QURE|MGTX: Market Cap to Projected Revenue|REGENXBIO Inc. - Forward P/S Multiple|ocugen.com (OCGN) - Forward Price-to-Revenue Multiple|PACB (PacBio) - Forward Price-to-Revenue Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Pharma|Rocket Corp (RCKT) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio 4D Molecular Therapeutics (FDMT)|Price-to-Projected Revenue Ratio LXEO (lexeotx.com)|Forward P/S Multiple KRRO (Korro Bio)|EDIT: Market Cap to Projected Revenue|Silence Therapeutics Inc. - Forward P/S Multiple|PRQR: Price-to-Projected Revenue Ratio|CDXS: Forward P/S Multiple|Market Cap to Projected Revenue SGMO|Price-to-Projected Revenue Ratio Nautilus Biotechnology, Inc.|Market Cap to Projected Revenue MGX (Metagenomi Inc.)|Forward P/S Multiple DTIL|Forward P/S Multiple generationbio.com (GBIO)|Price-to-Projected Revenue Ratio Boundless Bio, Inc. BOLD|Market Cap to Expected Sales Ratio Exicure Inc. (XCUR)|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals|mustangbio.com (MBIO) - Price-to-Projected Revenue Ratio|RNAZ (TransCode Therapeutics, Inc.) - Price-to-Projected Revenue Ratio|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|adnas.com (APDN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple BLUE|immunoprecise.com - Market Cap to Projected Revenue|Omega - Forward Price-to-Revenue Multiple|Forward Price to Sales OMIC|Regulus Therapeutics - Forward P/S Multiple|SYRS: Price-to-Projected Revenue Ratio|TBIO: Forward P/S Multiple|TCON - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Unity Bio